- Home
- QNCX vs TURN Comparison
QNCX vs TURN Comparison
Compare QNCX & TURN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNCX
- TURN
- Stock Information
- Founded
- QNCX 2012
- TURN 1981
- Country
- QNCX United States
- TURN United States
- Employees
- QNCX N/A
- TURN N/A
- Industry
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- TURN Finance/Investors Services
- Sector
- QNCX Health Care
- TURN Finance
- Exchange
- QNCX Nasdaq
- TURN Nasdaq
- Market Cap
- QNCX 47.7M
- TURN 39.9M
- IPO Year
- QNCX 2019
- TURN N/A
- Fundamental
- Price
- QNCX $1.31
- TURN $3.97
- Analyst Decision
- QNCX Strong Buy
- TURN
- Analyst Count
- QNCX 5
- TURN 0
- Target Price
- QNCX $8.00
- TURN N/A
- AVG Volume (30 Days)
- QNCX 302.6K
- TURN 16.9K
- Earning Date
- QNCX 08-12-2025
- TURN 08-18-2025
- Dividend Yield
- QNCX N/A
- TURN N/A
- EPS Growth
- QNCX N/A
- TURN N/A
- EPS
- QNCX N/A
- TURN N/A
- Revenue
- QNCX N/A
- TURN $194,813.00
- Revenue This Year
- QNCX N/A
- TURN N/A
- Revenue Next Year
- QNCX N/A
- TURN N/A
- P/E Ratio
- QNCX N/A
- TURN N/A
- Revenue Growth
- QNCX N/A
- TURN 254.25
- 52 Week Low
- QNCX $0.51
- TURN $3.12
- 52 Week High
- QNCX $2.45
- TURN $4.25
- Technical
- Relative Strength Index (RSI)
- QNCX 64.64
- TURN 46.15
- Support Level
- QNCX $1.29
- TURN $3.88
- Resistance Level
- QNCX $1.45
- TURN $4.00
- Average True Range (ATR)
- QNCX 0.09
- TURN 0.09
- MACD
- QNCX 0.03
- TURN -0.01
- Stochastic Oscillator
- QNCX 76.74
- TURN 45.45
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
About TURN 180 Degree Capital Corp.
180 Degree Capital Corp is active in the financial services domain. It is a non-diversified closed-end management investment company whose objective is to achieve long-term capital appreciation by making venture capital investments. It focuses its investments on companies commercializing and integrating products enabled by disruptive technologies mainly in the life sciences, precision medicine, and health industries.